Episode 2 - Talking Cardiovascular Disease Prevention: Emerging Strategies to Address Management Challenges in Dyslipidemia - Part 2: Dyslipidemia: Evidence-Based Personalized Treatment

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo ClinicDeepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1